By the Top Tier Newswire AI Desk · reviewed against 19 wire stories
VAXCYTE INC (PCVX) is up +36.23% in the latest session. Our newswire has captured 19 stories on PCVX across 11 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for PCVX publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
PCVX · today's session (5-min) · +36.08% vs prior close · updated 10:29 AM ETAI sentiment, last 36h · averaged over 19 stories · 63/100 bullish
The headlines behind the move
Story flow · 10 stories on the wire, last 36h · hover or tap a dot for the headline
5m agoMarketChameleonBULLISH 76Product/PR
PCVX rallies after OPUS-1 Phase 3 data show VAX-31 hit all primary endpoints and cleared 321 immunobridging comparisons
Vaxcyte reported positive topline Phase 3 OPUS-1 results for VAX-31, saying the 31-valent pneumococcal vaccine candidate met all prespecified primary endpoints in adults 50+ and achieved noninferiority across all 321 immunobridging comparisons in adults 18–49. The company said safety was similar to PCV20 and PCV21 and reiterated plans to read out OPUS-2 and OPUS-3 in 1H 2027 ahead of a planned BLA submission in 1H 2028.
8m agoBarron'sBULLISH 73Product/PR
Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
30m agoThe FlyBULLISH 64General
Vaxcyte rises 46.4%
34m agoThe FlyBEARISH 32General
Vaxcyte data hit ‘blue-sky’ case, says Jefferies
39m agoThe FlyBULLISH 67Analyst
Vaxcyte can trade in $90-$100 range on data, says Mizuho
1h agoInvestors.comBULLISH 67Product/PR
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study
2h agoInvestorsHubBULLISH 78Product/PR
Vaxcyte Shares Rise 50% After VAX-31 Meets Primary Endpoints in Phase 3 Trial
Vaxcyte shares rise 50% after its VAX-31 pneumococcal vaccine candidate met all prespecified primary endpoints in the pivotal OPUS-1 Phase 3 trial.
S&P 500 Futures Decline in Premarket Trading; Vaxcyte, PTC Lead
3h agoThe FlyBULLISH 61Analyst
Vaxcyte price target raised to $125 from $116 at Guggenheim
Frequently asked questions
Why is PCVX stock up today?
VAXCYTE INC (PCVX) is up +36.23% in the latest session. Our newswire has captured 19 stories on PCVX across 11 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100). The most recent driver: "PCVX rallies after OPUS-1 Phase 3 data show VAX-31 hit all primary endpoints and cleared 321 immunobridging comparisons" (MarketChameleon).
Is PCVX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of PCVX coverage reads 63/100 over 19 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →